Press release
Tumor Necrosis Factor Alpha (TNF-a) Inhibitors - Pipeline Insights 2017
Tumor Necrosis Factor Alpha (TNF-a) Inhibitors - Pipeline Insights 2017
View report:https://www.arizton.com/reports/pharma-pipeline-analysis/tumor-necrosis-factor-alpha-tnf-a-inhibitors-pipeline-insights
Key players developing potential TNF-a drug candidates have been profiled in the report. Each of the company profile provides details such as company overview, business overview, financial overview, product portfolio, business strategies, and recent developments.
Advent Tumor Necrosis Factor Alpha (TNF-a) inhibitors represent one a major treatment paradigm for inflammatory diseases. Anti TNF-a drug class one of the most commercially successful drug classes in the pharmaceutical industry worldwide. Currently marketed anti-TNF-a drugs are among the top five global block buster drugs. Cumulative sales of top three TNF-a inhibitors (Remicade, Enbrel, Humira) surpassed $32 billion in 2016.
TNF-a inhibitors exhibit therapeutic efficacy blocking the activity of tumor necrosis factor (TNF), a cytokine that causes inflammation and leads to diverse immune-system diseases. Apparently, almost all the currently marketed TNF-a drugs are indicated for wide spectrum of immune-related disorders such as – Crohn’s disease, ulcerative colitis, rheumatoid arthritis, ankylosing spondylitis, psoriatic arthritis, plaque psoriasis and uveitis. Advances in biological research is uncovering further therapeutic benefits of this drug class for wider indications. Currently clinical research is focused on evaluating therapeutic efficacy and safety of TNF-a inhibitors on wide range of other inflammatory diseases, neurodegenerative diseases and multiple cancers.
Reasons to buy
To gain erudite insights on TNF-a inhibitor pipeline landscape
Ascertain unique product development dynamics and leverage it for novel target identification, drug repositioning and precision medicine.
For optimization of pipeline product portfolio in correspondence with ever dynamic pharmaceutical market
Identify competitors and design strategic initiatives for drug development activities
To understand the market and choose right partners for strategic collaborations
To obtain well-informed updates on drug termination/drug discontinuations
Related Reports
1) Histone Deacetylase (HDAC) Inhibitors - Pipeline Insights 2017
https://www.arizton.com/reports/pharma-pipeline-analysis/histone-deacetylase-hdac-inhibitors-pipeline-insights
2) Chimeric Antigen Receptor (CAR) T Cell Immunotherapy - Pipeline Insights 2017
https://www.arizton.com/reports/pharma-pipeline-analysis/chimeric-antigen-receptor-car-t-cell-immunotherapy-pipeline-insights-2017
About Arizton
Arizton – Advisory and Intelligence is an innovation and quality-driven firm, which offers cutting-edge research solutions to clients across the world. We excel in providing comprehensive market intelligence reports and advisory and consulting services.
Arizton has gained a paramount standpoint in the market research arena as it offers top of the line solutions to clients to assess market landscape and to finalize foolproof business strategies. We are committed to provide inclusive market research reports and consulting services to clients from diversified industries including –Consumer Goods & Retail Technology, Automotive and Mobility, Smart Tech, Healthcare and Lifesciences, Industrial Machinery, Chemicals and Materials, IT and Media, Logistics and Packaging
Arizton comprises a team of exuberant and well-experienced analysts who have mastered in generating incisive reports. Our specialist analysts possess exemplary skills in market research. We train our team in advanced research practices, techniques, and ethics to outperform in fabricating impregnable research reports.
Arizton Advisory & Intelligence
Chicago, Illinois, 60605
Mail: enquiry@arizton.com
Call: +1-312-465-7864
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Tumor Necrosis Factor Alpha (TNF-a) Inhibitors - Pipeline Insights 2017 here
News-ID: 785375 • Views: …
More Releases from Arizton Advisory & Intelligence
The Sale of Construction Equipment in Latin America to Reach 145,985 Units by 20 …
According to the latest research report, the Latin America construction equipment market is growing at a CAGR of 3.43% during 2023-2029.
To Know More, Click: https://www.arizton.com/market-reports/latin-america-construction-equipment-market
Brazil stands as the premier hub within the Latin American market, commanding a formidable 40% share of construction equipment sales across the region in 2023. Notably, it serves as the epicenter for manufacturing construction equipment on the continent, with all significant OEMs establishing manufacturing…
The US Industrial Valve Market to Reach $11.02 Billion by 2029 - Exclusive Focus …
Arizton's latest research report shows that the US industrial valve market is growing at a CAGR of 4.28% from 2023-2029.
To Know More, Click: https://www.focusreports.store/report/us-industrial-valve-market-focused-insights
Cybersecurity takes center stage in the US industrial valves market as digital technologies become more integrated. Investments are actively made to secure valve systems against cyber threats to prevent unauthorized access and potential disruptions. Intrusion Detection Systems (IDS) are increasingly deployed to alert operators of potential security…
Malaysia Data Center Market to Witness $3.97 Billion Investment Opportunities by …
According to Arizton's latest research report, the Malaysia data center market is growing at a CAGR of 13.92% during the forecast period.
To Know More, Download the Free Sample Report: https://www.arizton.com/market-reports/malaysia-data-center-market-size-analysis
Over the next few years, Malaysia is poised to witness significant growth in data center investments, driven by the influx of operators like AirTrunk, Equinix, Princeton Digital Group, and other leading companies. Key hubs like Cyberjaya, Kuala Lumpur, and Johor…
The US Home Energy Management Systems Market to Reach $2.81 Billion by 2029 - Ar …
Arizton's latest research report shows that the US home energy management systems market is growing at a CAGR of 15.12% from 2023-2029.
To Know More, Click: https://www.focusreports.store/report/us-home-energy-management-systems-market-focused-insights
The US home energy management systems market is witnessing a surge in demand for various hardware, software, and services, driven by several emerging trends. Notably, the sustainable home energy management system trend is gaining momentum, fueled by eco-friendly solutions. This growth is propelled by…
More Releases for TNF
TNF Inhibitors Global Industry Report - History, Present and Future 2025
The global market size of TNF Inhibitors is $XX million in 2017 with XX CAGR from 2013 to 2017, and it is expected to reach $XX million by the end of 2023 with a CAGR of XX% from 2018 to 2023.
There are 3 key segments covered in this report: geography segment, end use/application segment and competitor segment.
For geography segment, regional supply, application-wise and type-wise demand, major players, price is presented…
TNF Inhibitors Market information related to pipeline products, news and deals
MarketResearchReports.Biz adds “Global TNF Inhibitors Market Share, Size, Trends and Forecast Market Research Report” reports to its database. This report provides a strategic analysis of the TNF Inhibitors and the growth estimates for the forecasted period.
The TNF inhibitors pipeline analysis report includes ongoing clinical and non-clinical trends in the global TNF inhibitors market. The anti-TNF drugs are among the top 10 global blockbuster drugs and have dominated the global pharmaceutical…
TNF Inhibitors Market Key Drivers & On-going Trends 2017 – 2025
TNF (tumor necrosis factor) inhibitors are anti-inflammatory drugs. TNF inhibitors help to block the TNF alpha that occurs naturally in the body and causes inflammation. TNF drugs are used to reduce inflammation and stop disease progression by targeting the tumor necrosis factor, which is an inflammation-causing substance. TNF inhibitor drugs are employed to treat inflammatory conditions such as rheumatoid arthritis and juvenile arthritis. Generally, in the healthy person, the TNF…
TNF Inhibitors Market Key Drivers & On-going Trends 2017 - 2025
TNF (tumor necrosis factor) inhibitors are anti-inflammatory drugs. TNF inhibitors help to block the TNF alpha that occurs naturally in the body and causes inflammation. TNF drugs are used to reduce inflammation and stop disease progression by targeting the tumor necrosis factor, which is an inflammation-causing substance.
View Report-
https://www.transparencymarketresearch.com/tnf-inhibitors-market.html
TNF inhibitor drugs are employed to treat inflammatory conditions such as rheumatoid arthritis and juvenile arthritis. Generally, in the healthy person, the…
TNF Inhibitors - A Pipeline Analysis Report
"The Report TNF Inhibitors - A Pipeline Analysis Report provides information on pricing, market analysis, shares, forecast, and company profiles for key industry participants. - MarketResearchReports.biz"
TNF Inhibitors: An insight
The TNF inhibitors pipeline analysis report includes ongoing clinical and non-clinical trends in the global TNF inhibitors market. The anti-TNF drugs are among the top 10 global blockbuster drugs and have dominated the global pharmaceutical market landscape for many years. The report…
Tumor Necrosis Factor Alpha (TNF-a) Inhibitors - Pipeline Insights 2017
“Tumor Necrosis Factor Alpha (TNF-a) Inhibitors-Pipeline Insights 2017″, report provides comprehensive analysis of TNF-a drug candidates currently undergoing clinical trials. The report covers detailed drug profiles of potential TNF-a inhibitors across various clinical development phases including – discovery, pre-clinical, IND, Phase I, Phase II, Phase III and Pre-registration. Report also includes the pipeline products’ clinical trial data along with information on other development activities including technology, licensing, collaborations, acquisitions, funding,…
